Glucagon resistance in fatty liver and diabetes
Part of Hormones & metabolism clinical trials.
This study looks at how people with fatty liver and type 2 diabetes respond to glucagon, a hormone that helps control blood sugar. It may help researchers understand a condition called 'glucagon resistance' and find better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a body mass index (BMI) over 26.
- You have been diagnosed with type 2 diabetes for at least 6 months.
- You have a fatty liver (more than 5.6% fat on specialized scans).
- You do not smoke or drink heavily (more than 10 drinks per week).
- You are not pregnant, and you have no history of cancer, heart attack, or heart failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at liver fat and how to manage it in people with obesity. It may help find better ways to treat fatty liver disease.
This research study looks at people with type 2 diabetes to learn more about fatty liver disease. By joining, you may help doctors better understand how these conditions are linked and improve future care.
This study tests a new way to measure how the brain uses sugar (glucose) to see if the hormone glucagon affects it. It may help researchers understand how certain hormones work in the body.
This study looks at how insulin and glucagon (hormones that control blood sugar) affect the liver. It may help us understand how the body regulates sugar and could lead to better treatments for diabetes.
This Phase 2 study tests how glucagon affects sugar and fat handling in the liver after a short period of calorie restriction. It may help researchers understand metabolic changes in people with type 2 diabetes and guide future treatments.
This study looks at how glucagon affects insulin release and blood sugar in people who do not have type 2 diabetes. It may help us understand normal glucose control better.
Hear when a new Metabolic Associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.